2,439 Shares in iShares Biotechnology ETF $IBB Purchased by Timbuktu Capital Management LLC

Timbuktu Capital Management LLC bought a new position in iShares Biotechnology ETF (NASDAQ:IBB) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,439 shares of the financial services provider’s stock, valued at approximately $464,000. iShares Biotechnology ETF comprises approximately 0.7% of Timbuktu Capital Management LLC’s portfolio, making the stock its 21st biggest holding.

Several other institutional investors and hedge funds have also recently modified their holdings of IBB. Bank of America Corp DE raised its stake in iShares Biotechnology ETF by 10.8% in the first quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after purchasing an additional 707,343 shares in the last quarter. Citigroup Inc. grew its stake in iShares Biotechnology ETF by 40.9% in the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after buying an additional 1,521,992 shares in the last quarter. Morgan Stanley grew its stake in iShares Biotechnology ETF by 2.5% in the 4th quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock worth $540,760,000 after buying an additional 76,978 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of iShares Biotechnology ETF by 11.4% in the 4th quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock worth $360,064,000 after buying an additional 218,066 shares during the last quarter. Finally, Raymond James Financial Inc. increased its holdings in shares of iShares Biotechnology ETF by 286.2% in the 4th quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock worth $167,810,000 after buying an additional 736,881 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

iShares Biotechnology ETF stock opened at $211.92 on Friday. iShares Biotechnology ETF has a fifty-two week low of $138.79 and a fifty-two week high of $217.12. The firm’s fifty day moving average price is $198.05 and its 200-day moving average price is $180.25.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were paid a $0.0238 dividend. This represents a $0.10 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date of this dividend was Monday, June 15th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.